<?xml version='1.0' encoding='utf-8'?>
<document id="21735354"><sentence text="Phase IB study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors."><entity charOffset="18-27" id="DDI-PubMed.21735354.s1.e0" text="sorafenib" /><entity charOffset="48-59" id="DDI-PubMed.21735354.s1.e1" text="gemcitabine" /><entity charOffset="64-73" id="DDI-PubMed.21735354.s1.e2" text="cisplatin" /><pair ddi="false" e1="DDI-PubMed.21735354.s1.e0" e2="DDI-PubMed.21735354.s1.e0" /><pair ddi="false" e1="DDI-PubMed.21735354.s1.e0" e2="DDI-PubMed.21735354.s1.e1" /><pair ddi="false" e1="DDI-PubMed.21735354.s1.e0" e2="DDI-PubMed.21735354.s1.e2" /><pair ddi="false" e1="DDI-PubMed.21735354.s1.e1" e2="DDI-PubMed.21735354.s1.e1" /><pair ddi="false" e1="DDI-PubMed.21735354.s1.e1" e2="DDI-PubMed.21735354.s1.e2" /></sentence><sentence text="Sorafenib (BAY 43-9006), a multikinase inhibitor, has been shown to inhibit tumor growth and tumor angiogenesis by targeting Raf kinase, vascular endothelial growth factor receptor, and platelet-derived growth factor receptor"><entity charOffset="0-9" id="DDI-PubMed.21735354.s2.e0" text="Sorafenib" /></sentence><sentence text=" This study investigated the safety, pharmacokinetics, and preliminary efficacy of sorafenib in combination with gemcitabine and cisplatin"><entity charOffset="83-92" id="DDI-PubMed.21735354.s3.e0" text="sorafenib" /><entity charOffset="113-124" id="DDI-PubMed.21735354.s3.e1" text="gemcitabine" /><entity charOffset="129-138" id="DDI-PubMed.21735354.s3.e2" text="cisplatin" /><pair ddi="false" e1="DDI-PubMed.21735354.s3.e0" e2="DDI-PubMed.21735354.s3.e0" /><pair ddi="false" e1="DDI-PubMed.21735354.s3.e0" e2="DDI-PubMed.21735354.s3.e1" /><pair ddi="false" e1="DDI-PubMed.21735354.s3.e0" e2="DDI-PubMed.21735354.s3.e2" /><pair ddi="false" e1="DDI-PubMed.21735354.s3.e1" e2="DDI-PubMed.21735354.s3.e1" /><pair ddi="false" e1="DDI-PubMed.21735354.s3.e1" e2="DDI-PubMed.21735354.s3.e2" /></sentence><sentence text="" /><sentence text="Patients with advanced solid tumors were treated with 75 mg/m(2) cisplatin on day 1 and 1,250 mg/m(2) gemcitabine on days 1 and 8 of each 21-day cycle"><entity charOffset="65-74" id="DDI-PubMed.21735354.s5.e0" text="cisplatin" /><entity charOffset="102-113" id="DDI-PubMed.21735354.s5.e1" text="gemcitabine" /><pair ddi="false" e1="DDI-PubMed.21735354.s5.e0" e2="DDI-PubMed.21735354.s5.e0" /><pair ddi="false" e1="DDI-PubMed.21735354.s5.e0" e2="DDI-PubMed.21735354.s5.e1" /></sentence><sentence text=" On day 5 of cycle 1, sorafenib 400 mg twice daily was started and continued throughout the complete treatment cycles without interruption" /><sentence text="" /><sentence text="Nineteen patients were valid for safety analysis" /><sentence text=" The most frequent toxicities related to the cytotoxic agents were hematological disorders" /><sentence text=" Sorafenib-related toxicities were skin-related, gastrointestinal, and constitutional symptoms"><entity charOffset="1-10" id="DDI-PubMed.21735354.s10.e0" text="Sorafenib" /></sentence><sentence text=" No clinically relevant pharmacokinetic drug-drug interaction between sorafenib, cisplatin, and gemcitabine was detected"><entity charOffset="70-79" id="DDI-PubMed.21735354.s11.e0" text="sorafenib" /><entity charOffset="81-90" id="DDI-PubMed.21735354.s11.e1" text="cisplatin" /><entity charOffset="96-107" id="DDI-PubMed.21735354.s11.e2" text="gemcitabine" /><pair ddi="false" e1="DDI-PubMed.21735354.s11.e0" e2="DDI-PubMed.21735354.s11.e0" /><pair ddi="false" e1="DDI-PubMed.21735354.s11.e0" e2="DDI-PubMed.21735354.s11.e1" /><pair ddi="false" e1="DDI-PubMed.21735354.s11.e0" e2="DDI-PubMed.21735354.s11.e2" /><pair ddi="false" e1="DDI-PubMed.21735354.s11.e1" e2="DDI-PubMed.21735354.s11.e1" /><pair ddi="false" e1="DDI-PubMed.21735354.s11.e1" e2="DDI-PubMed.21735354.s11.e2" /></sentence><sentence text=" AUC(0-72) and  C                            (max) of total and unbound platinum were only marginally changed by concomitant sorafenib"><entity charOffset="72-80" id="DDI-PubMed.21735354.s12.e0" text="platinum" /><entity charOffset="125-134" id="DDI-PubMed.21735354.s12.e1" text="sorafenib" /><pair ddi="false" e1="DDI-PubMed.21735354.s12.e0" e2="DDI-PubMed.21735354.s12.e0" /><pair ddi="false" e1="DDI-PubMed.21735354.s12.e0" e2="DDI-PubMed.21735354.s12.e1" /></sentence><sentence text=" Concomitant sorafenib increased mean AUC and  C                            (max) of gemcitabine by 12 and 21%"><entity charOffset="13-22" id="DDI-PubMed.21735354.s13.e0" text="sorafenib" /><entity charOffset="85-96" id="DDI-PubMed.21735354.s13.e1" text="gemcitabine" /><pair ddi="false" e1="DDI-PubMed.21735354.s13.e0" e2="DDI-PubMed.21735354.s13.e0" /><pair ddi="false" e1="DDI-PubMed.21735354.s13.e0" e2="DDI-PubMed.21735354.s13.e1" /></sentence><sentence text="" /><sentence text="Sorafenib as continuous oral treatment in combination with gemcitabine and cisplatin demonstrated an acceptable safety profile"><entity charOffset="0-9" id="DDI-PubMed.21735354.s15.e0" text="Sorafenib" /><entity charOffset="59-70" id="DDI-PubMed.21735354.s15.e1" text="gemcitabine" /><entity charOffset="75-84" id="DDI-PubMed.21735354.s15.e2" text="cisplatin" /><pair ddi="false" e1="DDI-PubMed.21735354.s15.e0" e2="DDI-PubMed.21735354.s15.e0" /><pair ddi="false" e1="DDI-PubMed.21735354.s15.e0" e2="DDI-PubMed.21735354.s15.e1" /><pair ddi="false" e1="DDI-PubMed.21735354.s15.e0" e2="DDI-PubMed.21735354.s15.e2" /><pair ddi="false" e1="DDI-PubMed.21735354.s15.e1" e2="DDI-PubMed.21735354.s15.e1" /><pair ddi="false" e1="DDI-PubMed.21735354.s15.e1" e2="DDI-PubMed.21735354.s15.e2" /></sentence><sentence text=" No clinically relevant pharmacokinetic interaction was detected" /><sentence text=" Preliminary antitumor activity, pharmacokinetic, and safety data support the recommendation of 400 mg sorafenib twice daily in combination with cisplatin and gemcitabine to be further evaluated in clinical studies"><entity charOffset="103-112" id="DDI-PubMed.21735354.s17.e0" text="sorafenib" /><entity charOffset="145-154" id="DDI-PubMed.21735354.s17.e1" text="cisplatin" /><entity charOffset="159-170" id="DDI-PubMed.21735354.s17.e2" text="gemcitabine" /><pair ddi="false" e1="DDI-PubMed.21735354.s17.e0" e2="DDI-PubMed.21735354.s17.e0" /><pair ddi="false" e1="DDI-PubMed.21735354.s17.e0" e2="DDI-PubMed.21735354.s17.e1" /><pair ddi="false" e1="DDI-PubMed.21735354.s17.e0" e2="DDI-PubMed.21735354.s17.e2" /><pair ddi="false" e1="DDI-PubMed.21735354.s17.e1" e2="DDI-PubMed.21735354.s17.e1" /><pair ddi="false" e1="DDI-PubMed.21735354.s17.e1" e2="DDI-PubMed.21735354.s17.e2" /></sentence><sentence text="" /></document>